Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

M

Mayo Clinic

Other

49

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

114

Indications↗

Distinct diseases across all programs

1,211

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

49 drugs in development

Approved12

Phase 35

Phase 222

Phase 126

Preclinical15

By Therapeutic Area

top 6

Oncology

3036%

Neurology

1012%

Cardiovascular

67%

Musculoskeletal

56%

Metabolic & Endocrine

34%

Infectious Disease

34%

R&D Momentum

100/100

Pipeline Velocity

84/100

Trial Completion Rate

76/100

Pipeline Concentration

19/100

Pipeline Freshness

68/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Enrolling by invitation

Analysis of Metal Ion Concentrations After Robotic-assisted Total Knee Arthroplasty Compared to Conventional Total Knee Arthroplasty

Active, not recruiting

Impact of Ketamine Versus Propofol for Anesthetic Induction on Acute Kidney Injury and Renal Biomarkers in Cardiac Surgery

Enrolling by invitation

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Protocol

Prospective Evaluation of Physician Modified Endografts for Aortic Disease

Seizure Detection With a Deep Brain Stimulation System

A Phase 1 Study Of The Safety And Immunogenicity Of Peptide-loaded Autologous Dendritic Cell Vaccination In Recurrent Respiratory Papillomatosis (RRP) Patients

MC1641 Phase II Study Of Intratumoral Injection Of Autologous Dendritic Cells Combined With Immune Checkpoint Inhibition After High-Dose Conformal External Beam Radiotherapy In Patients With Unresectable Primary Liver Cancer

Cardiopulmonary, Hemodynamic, And Symptom Responses To Aerobic And Resistance Exercise In Patients With Spontaneous Coronary Artery Dissection And Fibromuscular Dysplasia: A Single-center, Single-arm Prospective Clinical Trial.

Stellate Ganglion Blockade for the Prevention of Atrial Fibrillation After Cardiac Surgery: A Randomized Placebo-Controlled Trial

Rare Kidney Stone Consortium Registry for Hereditary Kidney Stone Diseases

Active, not recruiting

A Phase 2 Open-label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients With Active Lupus Nephritis

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(6 drugs)

3

1

3

—

—

Cardiovascular(6 drugs)

Dermatology(2 drugs)

2

—

1

—

—

Dermatology(2 drugs)

Gastroenterology(2 drugs)

—

—

1

—

1

Gastroenterology(2 drugs)

Hematology(1 drug)

—

—

1

—

—

Hematology(1 drug)

Immunology(2 drugs)

1

—

2

1

—

Immunology(2 drugs)

Infectious Disease(3 drugs)

—

—

3

—

—

Infectious Disease(3 drugs)

Metabolic & Endocrine(3 drugs)

1

3

—

—

1

Metabolic & Endocrine(3 drugs)

Musculoskeletal(5 drugs)

3

1

3

2

1

Musculoskeletal(5 drugs)

Nephrology(2 drugs)

—

—

1

—

1

Nephrology(2 drugs)

Neurology(10 drugs)

2

4

2

1

3

Neurology(10 drugs)

Oncology(30 drugs)

5

16

14

1

—

Oncology(30 drugs)

Rare Disease(1 drug)

1

—

1

—

—

Rare Disease(1 drug)

Respiratory(1 drug)

—

—

—

1

1

Respiratory(1 drug)

Unknown / Other(16 drugs)

5

7

3

1

6

Unknown / Other(16 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)